Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities.
Scientific Congress Publications
Supported by Bayer Pharmaceuticals
ASN 2026
Hyperkalemia in Finerenone-Treated Patients with CKD: A FIND-CKD Analysis
In the FIND-CKD study, finerenone raised serum [K+] independent of eGFR, UACR, and SGLT-2i use
Clinically serious hyperkalemia events were uncommon, and rates of hospitalization related to hyperkalemia were low; none were fatal
- As in diabetic CKD, determinants of hyperkalemia in nondiabetic CKD are:
- A higher baseline serum [K+] (>4.5 mmol/L)
- A lower eGFR (<45 mL/min/1.73 m2)
A higher UACR (>1000 mg/g)
- The same monitoring rules for serum [K+] apply to diabetic and nondiabetic CKD
© 2026 Bayer. All rights reserved.
Bayer and the Bayer Cross are registered trademarks of Bayer.
Copies of the Bayer Pharmaceuticals supported presentations obtained from this platform are for personal use only and may not be reproduced or distributed without permission from the authors.
Some of the compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities, and the presentations are shared in the interest of scientific exchange.
For any questions, please contact Medical Information at https://www.medicalinformation.bayer.com/
PP-GEN-ALL-0014-1
